| Johnson & Johnson (J&J) |
• Large, diversified portfolio and a long‑standing “risk‑management” culture.
• Successful defense in major product‑recall suits (e.g., talc lawsuits) in recent years.
• Strong capital base to absorb legal costs. |
• Proven track record of winning high‑profile cases.
• Extensive internal legal & compliance teams.
• High transparency in settlement disclosures. |
• Still faces thousands of lawsuits (e.g., opioid‑related claims).
• Settlements can be sizable, potentially impacting earnings.
• Regulatory scrutiny (e.g., FDA, FTC) can create additional litigation risk. |
| Pfizer |
• Successful defense of its COVID‑19 vaccine patents and supply‑chain disputes.
• Historically low number of class‑action settlements relative to peers.
• Robust litigation finance strategy (e.g., contingency‑fee arrangements). |
• Strong intellectual‑property portfolio gives leverage in patent suits.
• Large cash reserves cushion legal expenses.
• Transparent litigation reporting via SEC filings. |
• Ongoing patent disputes with generics (e.g., “Evergreening” allegations).
• Recent settlements on pricing/market‑sharing disputes.
• Potential exposure from new drug liability (e.g., rare‑disease therapies). |
| Merck & Co. |
• Successful litigation in key drug‑patent battles (e.g., Keytruda‑related lawsuits).
• Strong risk‑management processes in product liability claims.
• History of settling claims before trial when it’s in the company’s best interest. |
• Consistently ranked “Best in Class” for legal compliance.
• Low litigation‑cost ratio relative to peers.
• Strong disclosure culture. |
• Facing emerging litigation related to rare‑disease treatments (e.g., gene‑therapy patents).
• Potential exposure to global regulatory penalties.
• Settlement obligations may still be sizable. |
| Novartis |
• Successful defense of its ophthalmic drug patents (e.g., Lucentis).
• Reduced exposure through licensing agreements.
• Historically modest number of class actions. |
• Aggressive intellectual‑property strategy.
• Global presence reduces concentration of litigation in one jurisdiction.
• Transparent filing of litigation summaries in annual reports. |
• Some high‑profile drug‑recall suits (e.g., certain oncology drugs).
• Potential regulatory investigations in emerging markets.
• Settlements can be large for global product liability. |
| Roche |
• Strong defense record in diagnostic‑device litigation.
• Consistently high “Legal & Regulatory” ratings from independent rating agencies.
• Robust internal compliance & audit functions. |
• Low litigation‑related cost to revenue ratio.
• Transparent settlement disclosures.
• Strong emphasis on risk‑based |